Basic examination of anti-tumor effect and mechanism of anti-hypertensive drug telmisartan for hepatocellular carcinoma

2018 Fiscal Year Final Research Report

• Project/Area Number: 17H06915
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Applied pharmacology
• Research Institution: Kagawa University
• Principal Investigator: Toyota Yuka 香川大学, 医学部, 協力研究員 (00801565)
• Research Collaborator: Masaki Tutomu
• Project Period (FY): 2017-08-25 – 2019-03-31
• Keywords: 肝細胞癌 / 降圧薬テルミサルタン

Outline of Final Research Achievements

In 3 types (HLE, HLF, HepG2) of HCC cultured cell lines,telmisartan showed cell growth inhibitory effect, and 2 types (HuH-7, PLC / PRF / 5)were not delected anti-tumor effect.G1 arrest was observed due to the reduction in the expression of cyclinD1, Cdk4 and cyclinE induced from G1 to S phase of the cell cycle by the addition of telmisartan. Increased expression of phospho-p53 (Ser392) and decreased expression of survivin, increased degradation product of CCK-18 were detected, and induction of apoptosis were also observed.

Free Research Field

肝臓病学

Academic Significance and Societal Importance of the Research Achievements

降圧薬telmisartanはいくつかのHCC細胞株でmiRNAを介したG1アレストおよびアポトーシスの誘導を起こし、抗腫瘍効果を併せ持つ薬剤と考えられる。本研究は、今後高血圧や糖尿病性腎症を有するHCC患者にどの降圧薬を選択するかの１つの指針となる。